본문 바로가기
HOME> 논문 > 논문 검색상세

논문 상세정보

The American journal of medicine v.130 no.2, 2017년, pp.222 - 228   SCI SCIE
본 등재정보는 저널의 등재정보를 참고하여 보여주는 베타서비스로 정확한 논문의 등재여부는 등재기관에 확인하시기 바랍니다.

Impact of Body Mass Index and Genetics on Warfarin Major Bleeding Outcomes in a Community Setting

Hart, Ragan (Institute for Public Health Genetics, University of Washington, Seattle, Wash ) ; Veenstra, David L. (Institute for Public Health Genetics, University of Washington, Seattle, Wash ) ; Boudreau, Denise M. (Pharmaceutical Outcomes Research and Policy Program, University of Washington, Seattle, Wash ) ; Roth, Joshua A. (Pharmaceutical Outcomes Research and Policy Program, University of Washington, Seattle, Wash ) ;
  • 초록  

    Abstract Background Several studies have demonstrated an association between body mass index (BMI) and warfarin therapeutic dose, but none evaluated the association of BMI with the clinically important outcome of major bleeding in a community setting. To address this evidence gap, we conducted a case–control study to evaluate the association between BMI and major bleeding risk among patients receiving warfarin. Methods We used a case–control study design to evaluate the association between obesity (BMI >30.0 kg/m 2 ) and major bleeding risk among 265 cases and 305 controls receiving warfarin at Group Health, an integrated healthcare system in Washington State. Multivariate logistic regression was used to adjust for potential confounders derived from health plan records and a self-report survey. In exploratory analyses we evaluated the interaction between genetic variants potentially associated with warfarin bleeding ( CYP2C9 , VKORC1 , and CYP4F2 ) and obesity on the risk of major bleeding. Results Overall, the sample was 55% male, 94% Caucasian, and mean age was 70 years. Cases and controls had an average of 3.4 and 3.7 years of warfarin use, respectively. Obese patients had significantly lower major bleeding risk relative to non-obese patients (odds ratio [OR] 0.60, 95% confidence interval [CI] 0.39-0.92). The OR was 0.56 (95% CI 0.35-0.90) in patients with ≥1 year of warfarin use, and 0.78 (95% CI 0.40-1.54) in patients with CYP4F2*3 genetic status and obesity ( P = .049), suggesting a protective effect of obesity on the risk of major bleeding among those wild type for CYP4F2*3 , but not among variants. Conclusions Our findings suggest that BMI is an important clinical factor in assessing and managing warfarin therapy. Future studies should confirm the major bleeding associations, including the interaction between obesity and CYP4F2*3 status identified in this study, and evaluate potential mechanisms.


  • 주제어

    Body mass index .   CYP2C9 .   CYP4F2 .   Gene–environment interaction .   Major bleeding .   VKORC1 .   Warfarin.  

 활용도 분석

  • 상세보기

    amChart 영역
  • 원문보기

    amChart 영역

원문보기

무료다운로드
  • 원문이 없습니다.

유료 다운로드의 경우 해당 사이트의 정책에 따라 신규 회원가입, 로그인, 유료 구매 등이 필요할 수 있습니다. 해당 사이트에서 발생하는 귀하의 모든 정보활동은 NDSL의 서비스 정책과 무관합니다.

원문복사신청을 하시면, 일부 해외 인쇄학술지의 경우 외국학술지지원센터(FRIC)에서
무료 원문복사 서비스를 제공합니다.

NDSL에서는 해당 원문을 복사서비스하고 있습니다. 위의 원문복사신청 또는 장바구니 담기를 통하여 원문복사서비스 이용이 가능합니다.

이 논문과 함께 출판된 논문 + 더보기